RLMD

Relmada Therapeutics Stock Analysis

AI Rating

Neutral
  • Quality0/10
  • Growth↑ 5/10
  • Momentum↑ 9/10
Relmada Therapeutics sales and earnings growth
RLMD Growth
Neutral
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↑ 37.06%
  • FCF Y/Y↑ 24.84%
Relmada Therapeutics gross and profit margin trends
RLMD Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC↓ -296.10%
Relmada Therapeutics net debt vs free cash flow
RLMD Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Relmada Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗